Discovery of P3971 an Orally Efficacious Novel Anticancer Agent Targeting HIF-1 and STAT3 Pathways

E-ISSN： 1875-5992|13|9|1460-1466

ISSN： 1871-5206

Source： Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol.13, Iss.9, 2013-11, pp. : 1460-1466

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

STAT3, pSTAT3 and HIF1α are associated with vasculogenic mimicry and impact on survival in gastric adenocarcinoma

Oncology Letters, Vol. 8, Iss. 1, 2014-01 ,pp. : 431-437

Spandidos Publications

Access to resources Recommend Favorite

Therapeutically targeting the SUMOylation, Ubiquitination and Proteasome pathways as a novel anticancer strategy

By Driscoll James

Targeted Oncology, Vol. 5, Iss. 4, 2010-12 ,pp. : 281-289

Springer Publishing Company

Access to resources Recommend Favorite

The potential for targeting the STAT3 pathway as a novel therapy for melanoma

By Lesinski Gregory B

Future Oncology, Vol. 9, Iss. 7, 2013-07 ,pp. : 925-927

Future Medicine

Access to resources Recommend Favorite

SOCS3 blocks HIF-1α expression to inhibit proliferation and angiogenesis of human small cell lung cancer by downregulating activation of Akt, but not STAT3

Molecular Medicine Reports, Vol. 12, Iss. 1, 2015-01 ,pp. : 83-92

Spandidos Publications

Access to resources Recommend Favorite

Cytochrome P450 1B1: a novel anticancer therapeutic target

By McFadyen Morag CE Murray Graeme I

Future Oncology, Vol. 1, Iss. 2, 2005-04 ,pp. : 259-263

Future Medicine

Access to resources Recommend Favorite